Skip to main content
Signal8

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Drug Manufacturers - Specialty & Generic

Cardiol Therapeutics Inc. logo

Cardiol Therapeutics Inc.

NASDAQ:CRDLHealthcare
-7.12%$0.8824
Mkt Cap$112.68M
EV-
Float112.16M
O/S127.69M
VOL526K sh
$ Vol$471K
RVOL1.00×
Inst Own31.9%
Net Cash/Sh-
Dilution
Cardiol Therapeutics Inc. logoNASDAQ:CRDL$0.8824-7.12%
FormDescription
6-K
6-K
6-K
SUPPL
SEC Filing
13G/A
Beneficial Ownership Report (Amended)
6-K
SUPPL
SEC Filing
F-10/A
SEC Filing
6-K
6-K
6-K
6-K
F-X
SEC Filing
F-10
SEC Filing
6-K
13G/A
Beneficial Ownership Report (Amended)
6-K
6-K
6-K
6-K
6-K
6-K
6-K
13G/A
Beneficial Ownership Report (Amended)
6-K

1-25 of 189

…

Recent SEC filings with analysis

    Cardiol Therapeutics Inc. (CRDL) SEC Filings | Signal8